{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:14:12Z","timestamp":1783098852504,"version":"3.54.6"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,8]]},"abstract":"<jats:p>Vonoprazan, a novel acid suppressant and the first potassium-competitive acid blocker, has the potential to enhance the eradication rate of <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic> due to its robust acid-suppressing capacity. This study aimed to compare the efficacy of vonoprazan-based dual therapy (vonoprazan\u2013amoxicillin, VA) with vonoprazan-based bismuth quadruple therapy (VBQT) as a first-line treatment for <jats:italic toggle=\"yes\">H pylori<\/jats:italic> infection. This retrospective single-center non-inferiority study was conducted in China. Treatment-naive <jats:italic toggle=\"yes\">H pylori<\/jats:italic>-positive patients aged 18 to 80 received one of the 2 treatment regimens at our center. The VA group received vonoprazan 20\u2009mg twice daily and amoxicillin 1000\u2009mg 3 times daily for 14 days, whereas the VBQT group received vonoprazan 20\u2009mg, amoxicillin 1000\u2009mg, clarithromycin 500\u2009mg, and bismuth potassium citrate 220\u2009mg twice daily for 14 days. The eradication rate was evaluated 4 to 6 weeks after treatment using the carbon-13\/14 urea breath test. Propensity score matching was used to analyze eradication rates, adverse events (AEs), and patient compliance between the 2 groups. Initially, 501 patients were included, and after propensity score analysis, 156 patients were selected for the study. Intention-to-treat analysis showed eradication rates of 87.2% (95% CI, 79.8\u201394.6%) for the VA group and 79.5% (95% CI, 70.5\u201388.4%) for the VBQT group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.195). Per-protocol analysis demonstrated rates of 94.4% (95% CI, 89.2\u201399.7%) for the VA group and 96.8% (95% CI, 92.4\u2013100%) for the VBQT group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.507). Non-inferiority was confirmed between the 2 groups, with <jats:italic toggle=\"yes\">P<\/jats:italic> values\u2005&lt;\u2005.025. The VA group showed a lower rate of AEs (10.3% vs 17.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.250) compared to the VBQT group. There were no significant differences in patient compliance between the 2 groups. In treatment-naive patients with <jats:italic toggle=\"yes\">H pylori<\/jats:italic> infection, both the 14-day VA and VBQT regimens demonstrated comparable efficacy, with excellent eradication rates. Moreover, due to reduced antibiotic usage, lower rate of AEs, and lower costs, VA dual therapy should be prioritized.<\/jats:p>","DOI":"10.1097\/md.0000000000037476","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:02:08Z","timestamp":1709928128000},"page":"e37476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"Zhu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Institute of Digestive Disease, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases, The Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao-Rong","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-7842","authenticated-orcid":false,"given":"Feng-Yu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"e12514","DOI":"10.1111\/hel.12514","article-title":"Epidemiology of Helicobacter pylori infection.","volume":"23 Suppl 1","author":"Sjomina","year":"2018","journal-title":"Helicobacter"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jgh.15751","article-title":"Prevalence of Helicobacter pylori infection in China: a systematic review and meta-analysis.","volume":"37","author":"Ren","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis.","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.","volume":"348","author":"Ford","year":"2014","journal-title":"BMJ"},{"key":"R5-20250503","first-page":"745","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment.","volume":"42","year":"2022","journal-title":"Chin J Digestion"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report.","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"e12768","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm9061852","article-title":"The impact of gastric juice pH on the intraluminal therapy for Helicobacter pylori infection.","volume":"9","author":"Wang","year":"2020","journal-title":"J Clin Med"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis.","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"R10-20250503","first-page":"5027","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China.","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"R11-20250503","first-page":"7831","article-title":"Prevalence of antibiotic resistance of Helicobacter pylori isolates in Shanghai, China.","volume":"14","author":"Wang","year":"2022","journal-title":"Am J Transl Res"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","article-title":"The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas.","volume":"54","author":"Shen","year":"2022","journal-title":"Ann Med"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e14396","DOI":"10.1097\/MD.0000000000014396","article-title":"High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis.","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/phar.2662","article-title":"Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial.","volume":"42","author":"Guan","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17474124.2021.1826306","article-title":"The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection.","volume":"15","author":"Yun","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250503","first-page":"gutjnl-2023-329826","article-title":"Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials.","author":"Chen","year":"2023","journal-title":"Gut"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00535-020-01723-6","article-title":"Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.","volume":"55","author":"Okubo","year":"2020","journal-title":"J Gastroenterol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1751-2980.13166","article-title":"Vonoprazan is non-inferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a propensity score matching analysis.","volume":"24","author":"Wang","year":"2023","journal-title":"J Dig Dis"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jgh.15837","article-title":"Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.","volume":"37","author":"Hou","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5152\/tjg.2022.211041","article-title":"Vonoprazan on the eradication of Helicobacter pylori infection.","volume":"34","author":"Huang","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s10238-023-01074-5","article-title":"Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.","volume":"23","author":"Peng","year":"2023","journal-title":"Clin Exp Med"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"17562848231190976","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial.","volume":"16","author":"Wang","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China.","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"e35610","DOI":"10.1097\/MD.0000000000035610","article-title":"A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori.","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jcpt.13637","article-title":"Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials.","volume":"47","author":"Yang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"799","DOI":"10.5009\/gnl20242","article-title":"Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication?","volume":"15","author":"Sue","year":"2021","journal-title":"Gut Liver"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcp.14934","article-title":"Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.","volume":"88","author":"Huh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11894-011-0226-4","article-title":"Gastric infection by Helicobacter pylori.","volume":"13","author":"Sachs","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.","volume":"39","author":"Erah","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11938-018-0206-y","article-title":"Potent acid suppression with PPIs and P-CABs: what\u2019s new?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/ph13100276","article-title":"The potential benefits of vonoprazan as Helicobacter pylori infection therapy.","volume":"13","author":"Miftahussurur","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"e12597","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition.","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"e12692","DOI":"10.1111\/hel.12692","article-title":"PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis.","volume":"25","author":"Gao","year":"2020","journal-title":"Helicobacter"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12876-023-02890-5","article-title":"Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"987","DOI":"10.21037\/atm-22-4133","article-title":"The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study.","volume":"10","author":"Lin","year":"2022","journal-title":"Ann Transl Med"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"e12896","DOI":"10.1111\/hel.12896","article-title":"Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: a prospective, randomized clinical pilot study.","volume":"27","author":"Hu","year":"2022","journal-title":"Helicobacter"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy.","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"e13003","DOI":"10.1111\/hel.13003","article-title":"Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: a propensity score matching analysis.","volume":"28","author":"Su","year":"2023","journal-title":"Helicobacter"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united states and Europe: randomized clinical trial.","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000519413","article-title":"The ideal Helicobacter pylori treatment for the present and the future.","volume":"103","author":"Suzuki","year":"2022","journal-title":"Digestion"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"1049908","DOI":"10.3389\/fimmu.2022.1049908","article-title":"Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study.","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"R46-20250503","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12383","article-title":"Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children.","volume":"22","author":"Kotilea","year":"2017","journal-title":"Helicobacter"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.0306-5251.2001.01531.x","article-title":"Management of Helicobacter pylori eradication \u2013 the influence of structured counselling and follow-up.","volume":"53","author":"Al-Eidan","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"e12890","DOI":"10.1111\/hel.12890","article-title":"Does technology-enhanced communication improve Helicobacter pylori eradication outcomes? \u2013 A meta-analysis.","volume":"27","author":"Chua","year":"2022","journal-title":"Helicobacter"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:21:35Z","timestamp":1746318095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037476","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}